Safety, immunogenicity of two doses of the HPV-16/18 AS04 adjuvanted vaccine Cervarix
Saturday, March 29, 2014 - 14:20
in Health & Medicine
Two doses of the HPV-16/18 AS04-adjuvanted vaccine Cervarix (GlaxoSmithKline) are non-inferior to three-doses in the current schedule, research shows. Since high coverage and compliance rates can be difficult to achieve with the current three-dose HPV vaccineregimen, several studies have looked at the possibility of reducing the number of doses. Proof-of-principle that a two-dose schedule can provide sufficient protection against cervical cancer came initially from a study performed in Costa Rica in 2011.